Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to commercialize ...
Regenxbio CEO Curran Simpson at Endpoints' #JPM26 event (Brian Benton Photography) May 14, 2026 07:00 AM EDT Cell/Gene TxFDA+ Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA? Lei Lei Wu News Reporter Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027.
… Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that